| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8324225 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Jun, 2028
(4 years from now) | |
| US8685980 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
May, 2030
(6 years from now) | |
| US8415355 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Mar, 2031
(6 years from now) | |
| US9193732 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9416136 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Aug, 2029
(5 years from now) | |
| US8962630 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Dec, 2029
(5 years from now) | |
| US9868739 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(7 years from now) | |
| US10799506 | NOVARTIS | Ribociclib tablet |
Apr, 2036
(11 years from now) | |
Kisqali Femara Co-Pack (Copackaged) is owned by Novartis.
Kisqali Femara Co-Pack (Copackaged) contains Letrozole; Ribociclib Succinate.
Kisqali Femara Co-Pack (Copackaged) has a total of 8 drug patents out of which 0 drug patents have expired.
Kisqali Femara Co-Pack (Copackaged) was authorised for market use on 04 May, 2017.
Kisqali Femara Co-Pack (Copackaged) is available in tablet;oral dosage forms.
Kisqali Femara Co-Pack (Copackaged) can be used as as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer.
Drug patent challenges can be filed against Kisqali Femara Co-Pack (Copackaged) from 13 March, 2021.
The generics of Kisqali Femara Co-Pack (Copackaged) are possible to be released after 14 April, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 10, 2024 |
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2022 |
Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient
NCE-1 date: 13 March, 2021
Market Authorisation Date: 04 May, 2017
Treatment: As initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cance...
Dosage: TABLET;ORAL
KISQALI FEMARA CO-PACK (COPACKAGED) family patents
